Roivant Q2 loss $236.8M; Dermavant deal closed; cash $5.4B; brepocitinib NIU data

Roivant Sciences Ltd.

2024-Q2 EPS reported -$0.18 revenue$12,465,000

Q2 loss from continuing ops $236.8M ($0.25 EPS); R&D $143.1M; G&A $202.9M up $114.3M YoY on retention awards.
Dermavant transaction closed Oct 28: Roivant received $184M cash; Organon assumed $336M debt; $75M milestone pending VTAMA FDA approval for atopic dermatitis.
Consolidated cash, cash equivalents and marketable securities ~$5.4B at Sep 30, 2024.
Share repurchases $106M in Q2; cumulative $754M (incl. Sumitomo stake buyback).
Pipeline: brepocitinib Phase 2 NIU 52-wk data shows sustained efficacy; batoclimab GD 76% response; mosliciguat PVR reduction ~38%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.